These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24827829)

  • 41. An overexpression of fibroblast growth factor (FGF) and FGF receptor 4 in a severe clinical phenotype of facioscapulohumeral muscular dystrophy.
    Saito A; Higuchi I; Nakagawa M; Saito M; Uchida Y; Inose M; Kasai T; Niiyama T; Fukunaga H; Arimura K; Osame M
    Muscle Nerve; 2000 Apr; 23(4):490-7. PubMed ID: 10716758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Facioscapulohumeral muscular dystrophy presenting isolated monomelic lower limb atrophy. Report of two patients with and without 4q35 rearrangement.
    Uncini A; Galluzzi G; Di Muzio A; De Angelis MV; Ricci E; Scoppetta C; Servidei S
    Neuromuscul Disord; 2002 Nov; 12(9):874-7. PubMed ID: 12398841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug treatment for facioscapulohumeral muscular dystrophy.
    Rose MR; Tawil R
    Cochrane Database Syst Rev; 2004; 2004(2):CD002276. PubMed ID: 15106171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic Myopathy Associated With Anti-Signal Recognition Particle Antibodies Can Be Misdiagnosed As Facioscapulohumeral Muscular Dystrophy.
    Ikeda K; Mori-Yoshimura M; Yamamoto T; Sonoo M; Suzuki S; Kondo Y; Nakamura H; Mitsuhashi K; Maeda MH; Shimizu J; Hayashi YK; Nishino I; Oya Y; Murata M
    J Clin Neuromuscul Dis; 2016 Jun; 17(4):197-206. PubMed ID: 27224434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
    Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
    Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Facioscapulohumeral muscular dystrophy presenting with hypertrophic cardiomyopathy: a case study.
    Tsuji M; Kinoshita M; Imai Y; Kawamoto M; Kohara N
    Neuromuscul Disord; 2009 Feb; 19(2):140-2. PubMed ID: 19147353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Shank sign in myotonic dystrophy type-1 (DM-1).
    Pradhan S
    J Clin Neurosci; 2007 Jan; 14(1):27-32. PubMed ID: 17092719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isokinetic assessment of trunk muscles in facioscapulohumeral muscular dystrophy type 1 patients.
    Esnault J; Missaoui B; Bendaya S; Mane M; Eymard B; Laforet P; Stojkovic T; Behin A; Thoumie P
    Neuromuscul Disord; 2018 Dec; 28(12):996-1002. PubMed ID: 30415787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical, muscle pathological, and genetic features of Japanese facioscapulohumeral muscular dystrophy 2 (FSHD2) patients with SMCHD1 mutations.
    Hamanaka K; Goto K; Arai M; Nagao K; Obuse C; Noguchi S; Hayashi YK; Mitsuhashi S; Nishino I
    Neuromuscul Disord; 2016; 26(4-5):300-8. PubMed ID: 27061275
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sarcolemmal reorganization in facioscapulohumeral muscular dystrophy.
    Reed P; Porter NC; Strong J; Pumplin DW; Corse AM; Luther PW; Flanigan KM; Bloch RJ
    Ann Neurol; 2006 Feb; 59(2):289-97. PubMed ID: 16437580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging preclinical animal models for FSHD.
    Lek A; Rahimov F; Jones PL; Kunkel LM
    Trends Mol Med; 2015 May; 21(5):295-306. PubMed ID: 25801126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis of dystrophinopathy by skin biopsy.
    Niiyama T; Higuchi I; Sakoda S; Matsumura T; Fukunaga H; Osame M
    Muscle Nerve; 2002 Mar; 25(3):398-401. PubMed ID: 11870717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones PL
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():265-291. PubMed ID: 31018108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy.
    Lassche S; Voermans NC; Schreuder T; Heerschap A; Küsters B; Ottenheijm CA; Hopman MT; van Engelen BG
    Muscle Nerve; 2021 Jan; 63(1):60-67. PubMed ID: 32959362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI.
    Olsen DB; Gideon P; Jeppesen TD; Vissing J
    J Neurol; 2006 Nov; 253(11):1437-41. PubMed ID: 16773269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term results of scapulothoracic arthrodesis of facioscapulohumeral muscular dystrophy.
    Rhee YG; Ha JH
    J Shoulder Elbow Surg; 2006; 15(4):445-50. PubMed ID: 16831649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Facioscapulohumeral muscular dystrophy: Report of seven patients].
    Cea G; Jiménez D
    Rev Med Chil; 2015 Mar; 143(3):304-9. PubMed ID: 26005816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FSHD-like patients without 4q35 deletion.
    Yamanaka G; Goto K; Ishihara T; Oya Y; Miyajima T; Hoshika A; Nishino I; Hayashi YK
    J Neurol Sci; 2004 Apr; 219(1-2):89-93. PubMed ID: 15050443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Respiratory function in facioscapulohumeral muscular dystrophy 1.
    Wohlgemuth M; Horlings CGC; van der Kooi EL; Gilhuis HJ; Hendriks JCM; van der Maarel SM; van Engelen BGM; Heijdra YF; Padberg GW
    Neuromuscul Disord; 2017 Jun; 27(6):526-530. PubMed ID: 28416348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Great Athlete with Muscular Weakness.
    Bourguiba R; Masingue M; Marc PJ; Lenglet T; Bachmeyer C
    Am J Med; 2021 Feb; 134(2):e109-e110. PubMed ID: 32835688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.